Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP-STAR: EBV DNA-guided Treatment Adaptation in High Risk Nasopharyngeal Carcinoma
NCT04072107Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2020
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
sintilimabcapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04072107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04072107.